PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22608542-12 2013 The use of high-dose vandetanib alone may warrant further investigation in patients with docetaxel-resistant AIPC overexpressing VEGFR/EGFR pathways. Docetaxel 89-98 epidermal growth factor receptor Homo sapiens 130-134 34527325-3 2021 Methods: This retrospective, single-institution cohort study reports outcomes of patients who received docetaxel with or without ramucirumab according to EGFR status. Docetaxel 103-112 epidermal growth factor receptor Homo sapiens 154-158 34976813-3 2021 We aimed to evaluate the efficacy and safety of docetaxel/sodium cantharidinate combination vs. either agent alone as second-line treatment for advanced/metastatic NSCLC patients with wild-type or unknown EGFR status. Docetaxel 48-57 epidermal growth factor receptor Homo sapiens 205-209 34292495-2 2021 We evaluated the outcomes of the combination of docetaxel plus nintedanib in refractory NSCLC patients harboring EGFR mutations. Docetaxel 48-57 epidermal growth factor receptor Homo sapiens 113-117 34292495-3 2021 METHODS: We retrospectively analyzed 19 patients with advanced EGFR-mutant NSCLC who had progressed to EGFR tyrosine kinase inhibitors (TKI) and platinum-based chemotherapy receiving docetaxel and nintedanib at 14 Spanish institutions from January 2013 to December 2019. Docetaxel 183-192 epidermal growth factor receptor Homo sapiens 63-67 34292495-19 2021 CONCLUSIONS: Our data indicate that the combination of docetaxel and nintedanib can be considered to be an effective treatment for EGFR TKI-resistant EGFR-mutant NSCLC. Docetaxel 55-64 epidermal growth factor receptor Homo sapiens 150-154 34795944-0 2021 Correlation of EGFR G873R mutation with prognosis of docetaxel in non-small cell lung cancer. Docetaxel 53-62 epidermal growth factor receptor Homo sapiens 15-19 34795944-11 2021 Patients with EGFR G873R mutation had a significantly favorable prognosis of docetaxel (P=0.032), and for patients treated with docetaxel, EGFR G873R mutation was significantly correlated with better 5-year disease-free survival (DFS; P=0.026) and overall survival (OS; P=0.026). Docetaxel 77-86 epidermal growth factor receptor Homo sapiens 14-18 34795944-11 2021 Patients with EGFR G873R mutation had a significantly favorable prognosis of docetaxel (P=0.032), and for patients treated with docetaxel, EGFR G873R mutation was significantly correlated with better 5-year disease-free survival (DFS; P=0.026) and overall survival (OS; P=0.026). Docetaxel 128-137 epidermal growth factor receptor Homo sapiens 14-18 34795944-11 2021 Patients with EGFR G873R mutation had a significantly favorable prognosis of docetaxel (P=0.032), and for patients treated with docetaxel, EGFR G873R mutation was significantly correlated with better 5-year disease-free survival (DFS; P=0.026) and overall survival (OS; P=0.026). Docetaxel 128-137 epidermal growth factor receptor Homo sapiens 139-143 34795944-13 2021 Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. Docetaxel 81-90 epidermal growth factor receptor Homo sapiens 13-17 34795944-13 2021 Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. Docetaxel 81-90 epidermal growth factor receptor Homo sapiens 122-126 34795944-13 2021 Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. Docetaxel 223-232 epidermal growth factor receptor Homo sapiens 13-17 34795944-13 2021 Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. Docetaxel 223-232 epidermal growth factor receptor Homo sapiens 122-126 34445110-0 2021 Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer. Docetaxel 44-53 epidermal growth factor receptor Homo sapiens 58-62 34445110-8 2021 Moreover, SH003 and DTX induced the apoptosis of H460 cells via the suppression of the EGFR and signal transducer and activator of transcription 3 (STAT3) signaling pathways. Docetaxel 20-23 epidermal growth factor receptor Homo sapiens 87-91 34445110-9 2021 In H460 tumor xenograft models, the administration of SH003 or docetaxel alone diminished tumor growth, and their combination effectively killed cancer cells, with increased expression of apoptotic markers and decreased expression of p-EGFR and p-STAT3. Docetaxel 63-72 epidermal growth factor receptor Homo sapiens 236-240 34527325-6 2021 Results: Patients in the EGFR-doce/ram cohort had a median time on docetaxel of 1.4 months (95% CI: 0.72-5.2 months) and of 0.8 months (95% CI: 0.2-6.5 months) on ramucirumab. Docetaxel 67-76 epidermal growth factor receptor Homo sapiens 25-29 35572726-0 2022 SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer. Docetaxel 10-19 epidermal growth factor receptor Homo sapiens 70-74 34140769-1 2021 Purpose: This study was aimed at developing the trispecific antibodies (anti-EGFR/anti-FAP/anti-mPEG, TsAb) or dual bispecific antibodies (anti-EGFR/anti-mPEG and anti-FAP/anti-mPEG) docetaxel (DTX)-loaded mPEGylated lecithin-stabilized micelles (mPEG-lsbPMs) for improving the targeting efficiency and therapeutic efficacy. Docetaxel 194-197 epidermal growth factor receptor Homo sapiens 144-148 35572726-7 2022 Mechanistically, the cotreatment of SH003 and DTX inhibited phosphorylation of EGFR and AKT in both BT-20 and MDA-MB-231 cells. Docetaxel 46-49 epidermal growth factor receptor Homo sapiens 79-83 32924987-8 2021 Gene set variation analysis (GSVA) showed that activity in the cell cycle/mitotic, ERBB, and ERK/MAPK pathways was higher in the high-risk compared with the low-risk group, which may lead to differences in OS.Interestingly, we observed that patients in the high-risk group were more sensitive to gemcitabine and docetaxel than the low-risk group, which is consistent with results of the GSVA. Docetaxel 312-321 epidermal growth factor receptor Homo sapiens 83-87 34026617-2 2021 In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-kappaB activation. Docetaxel 155-164 epidermal growth factor receptor Homo sapiens 249-281 33169187-11 2021 Gefitinib/docetaxel co-administration demonstrated synergy suggesting taxanes could be the most effective cytotoxic partner for anti-EGFR therapies in EGFR CNG-positive ESCC, but careful consideration of drug scheduling is required. Docetaxel 10-19 epidermal growth factor receptor Homo sapiens 133-137 33169187-11 2021 Gefitinib/docetaxel co-administration demonstrated synergy suggesting taxanes could be the most effective cytotoxic partner for anti-EGFR therapies in EGFR CNG-positive ESCC, but careful consideration of drug scheduling is required. Docetaxel 10-19 epidermal growth factor receptor Homo sapiens 151-155 32574928-0 2020 EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells. Docetaxel 50-59 epidermal growth factor receptor Homo sapiens 0-4 32574928-12 2020 To the best of our knowledge, this is the first report of engineering EGFR-targeted liposomes to enhance the selectivity of DTX delivery to EGFR-positive prostate cancer cells. Docetaxel 124-127 epidermal growth factor receptor Homo sapiens 70-74 32574928-12 2020 To the best of our knowledge, this is the first report of engineering EGFR-targeted liposomes to enhance the selectivity of DTX delivery to EGFR-positive prostate cancer cells. Docetaxel 124-127 epidermal growth factor receptor Homo sapiens 140-144 32271354-17 2020 Conclusions and Relevance: In this phase 2 study, the combination of pembrolizumab plus docetaxel was well tolerated and substantially improved ORR and PFS in patients with advanced NSCLC who had previous progression after platinum-based chemotherapy, including NSCLC with EGFR variations. Docetaxel 88-97 epidermal growth factor receptor Homo sapiens 273-277 32642151-0 2020 Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. Docetaxel 28-37 epidermal growth factor receptor Homo sapiens 123-127 32642151-11 2020 Conclusions: Apatinib plus docetaxel is an effective and tolerable treatment option for advanced non-squamous NSCLC with wild-type EGFR. Docetaxel 27-36 epidermal growth factor receptor Homo sapiens 131-135 30760168-3 2020 We present a case of a 78-year-old man who was diagnosed with stage IV non-small cell lung adenocarcinoma with an EGFR exon 20 mutations treated with pemetrexed, nivolumab, and then docetaxel. Docetaxel 182-191 epidermal growth factor receptor Homo sapiens 114-118 32464632-0 2020 The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. Docetaxel 117-126 epidermal growth factor receptor Homo sapiens 14-18 31553438-1 2019 BACKGROUND: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Docetaxel 281-290 epidermal growth factor receptor Homo sapiens 204-208 31285646-1 2019 Epidermal Growth Factor Receptor (EGFR) is, for the most part, deregulated and over-communicated in ovarian disease, which is legitimately connected with STAT3 enactment that prompts the collection of hostile to apoptotic occasions and along these lines, docetaxel medicate obstruction happens. Docetaxel 255-264 epidermal growth factor receptor Homo sapiens 0-32 31388299-0 2019 In vivo evaluation of cetuximab-conjugated poly(gamma-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]. Docetaxel 69-78 epidermal growth factor receptor Homo sapiens 96-100 31285646-1 2019 Epidermal Growth Factor Receptor (EGFR) is, for the most part, deregulated and over-communicated in ovarian disease, which is legitimately connected with STAT3 enactment that prompts the collection of hostile to apoptotic occasions and along these lines, docetaxel medicate obstruction happens. Docetaxel 255-264 epidermal growth factor receptor Homo sapiens 34-38 31285646-2 2019 As to, expanding of docetaxel medicate affectability by focusing on EGFR receptor alongside docetaxel drugs is one of the real techniques in ovarian disease treatment. Docetaxel 20-29 epidermal growth factor receptor Homo sapiens 68-72 30368503-0 2019 Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program. Docetaxel 92-101 epidermal growth factor receptor Homo sapiens 10-42 30719215-5 2019 Results suggest that patients with NSCLC and EGFR mutation, previously treated with TKIs, show better OS when treated with docetaxel in comparison to checkpoint inhibitors treatment. Docetaxel 123-132 epidermal growth factor receptor Homo sapiens 45-49 30368503-11 2019 CONCLUSIONS: Our data indicated that nintedanib-docetaxel combination could be considered to be effective treatment in EGFR TKI-resistant EGFR mutant NSCLC. Docetaxel 48-57 epidermal growth factor receptor Homo sapiens 119-123 30368503-11 2019 CONCLUSIONS: Our data indicated that nintedanib-docetaxel combination could be considered to be effective treatment in EGFR TKI-resistant EGFR mutant NSCLC. Docetaxel 48-57 epidermal growth factor receptor Homo sapiens 138-142 30066906-2 2018 We have previously reported that the combined inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) led to an increased antitumor activity of docetaxel in CRPC. Docetaxel 171-180 epidermal growth factor receptor Homo sapiens 60-92 30226780-0 2018 Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy. Docetaxel 70-79 epidermal growth factor receptor Homo sapiens 109-113 30066906-2 2018 We have previously reported that the combined inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) led to an increased antitumor activity of docetaxel in CRPC. Docetaxel 171-180 epidermal growth factor receptor Homo sapiens 94-98 30066906-9 2018 The enhanced expression of EGFR and COX-2 was observed in docetaxel-resistant CRPC relative to the parental cell lines. Docetaxel 58-67 epidermal growth factor receptor Homo sapiens 27-31 30066906-14 2018 In conclusion, the combined inhibition of EGFR and COX-2 by gefitinib and celecoxib may overcome docetaxel resistance in human CRPC. Docetaxel 97-106 epidermal growth factor receptor Homo sapiens 42-46 29843041-0 2018 Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles. Docetaxel 106-115 epidermal growth factor receptor Homo sapiens 0-34 29115057-10 2018 CONCLUSIONS: Smoking history and EGFR status may help predict the performance of PD-(L)1 inhibitors vs docetaxel in previously treated NSCLC patients. Docetaxel 103-112 epidermal growth factor receptor Homo sapiens 33-37 29599351-0 2018 Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. Docetaxel 114-123 epidermal growth factor receptor Homo sapiens 24-30 29599351-1 2018 BACKGROUND: Chemotherapy with trastuzumab, pertuzumab and docetaxel (TPD regimen) is now strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER)2-positive breast cancer. Docetaxel 58-67 epidermal growth factor receptor Homo sapiens 174-206 29542378-0 2018 Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Docetaxel 52-61 epidermal growth factor receptor Homo sapiens 93-97 29615076-1 2018 BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Docetaxel 45-54 epidermal growth factor receptor Homo sapiens 157-189 29290252-3 2018 The superiority of single agent PD-1/PD-L1 inhibitors over docetaxel in pre-treated EGFR mutant NSCLC appears to be moderated. Docetaxel 59-68 epidermal growth factor receptor Homo sapiens 84-88 29082855-1 2017 BACKGROUND: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). Docetaxel 12-21 epidermal growth factor receptor Homo sapiens 186-218 29082855-1 2017 BACKGROUND: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). Docetaxel 12-21 epidermal growth factor receptor Homo sapiens 220-224 28122302-2 2017 In this report, we designed EGFR peptide decorated nanoparticles (NPs) to co-deliver docetaxel (DTX) and pH sensitive curcumin (CUR) prodrug for the treatment of prostate cancer. Docetaxel 85-94 epidermal growth factor receptor Homo sapiens 28-32 28959367-11 2017 The results of the present study revealed that docetaxel-resistant NSCLC cells also acquired cross-resistance to EGFR-TKI therapy through mechanisms other than ABCB1, that ABCB1 serves an important role in acquired resistance to docetaxel in lung cancer, and that combination therapy with elacridar can overcome ABCB1-mediated docetaxel resistance. Docetaxel 47-56 epidermal growth factor receptor Homo sapiens 113-117 29033568-0 2017 In vivo evaluation of cetuximab-conjugated poly(gamma-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts. Docetaxel 69-78 epidermal growth factor receptor Homo sapiens 96-100 29033568-2 2017 This study demonstrates in silico modeling of monoclonal antibody cetuximab (CET MAb)-conjugated docetaxel (DOCT)-loaded poly(gamma-glutamic acid) (gamma-PGA) nanoparticles (Nps) and evaluates the in vitro/in vivo effects on EGFR-overexpressing gastric cancer cells (MKN-28). Docetaxel 97-106 epidermal growth factor receptor Homo sapiens 225-229 29033568-2 2017 This study demonstrates in silico modeling of monoclonal antibody cetuximab (CET MAb)-conjugated docetaxel (DOCT)-loaded poly(gamma-glutamic acid) (gamma-PGA) nanoparticles (Nps) and evaluates the in vitro/in vivo effects on EGFR-overexpressing gastric cancer cells (MKN-28). Docetaxel 108-112 epidermal growth factor receptor Homo sapiens 225-229 29033568-7 2017 Thus, actively targeted CET MAb-DOCT-gamma-PGA Nps could be developed as a substitute to conventional nonspecific chemotherapy, and hence could become a feasible strategy for cancer therapy for EGFR-overexpressing gastric tumors. Docetaxel 32-36 epidermal growth factor receptor Homo sapiens 194-198 28122302-2 2017 In this report, we designed EGFR peptide decorated nanoparticles (NPs) to co-deliver docetaxel (DTX) and pH sensitive curcumin (CUR) prodrug for the treatment of prostate cancer. Docetaxel 96-99 epidermal growth factor receptor Homo sapiens 28-32 28122302-3 2017 RESULTS: EGFR peptide (GE11) targeted, pH sensitive, DTX and CUR prodrug NPs (GE11-DTX-CUR NPs) had an average diameter of 167nm and a zeta potential of -37.5mV. Docetaxel 53-56 epidermal growth factor receptor Homo sapiens 9-13 28337370-8 2017 Phase II/III clinical trials showed that combinatorial treatment of tyrosine kinase (TK)-inhibitors with chemotherapeutics, such as docetaxel and pemetrexed, caused significant improvements in progression-free survival and overall survival.Phase I and II clinical studies also revealed that combination of tyrosine kinase-inhibitors with the EGFR-targeted antibodies was an effective approach for treating lung cancer. Docetaxel 132-141 epidermal growth factor receptor Homo sapiens 342-346 28017787-2 2017 INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Docetaxel 14-23 epidermal growth factor receptor Homo sapiens 90-94 27916908-0 2016 Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. Docetaxel 170-179 epidermal growth factor receptor Homo sapiens 0-32 27274999-0 2016 Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. Docetaxel 29-38 epidermal growth factor receptor Homo sapiens 163-167 27221512-11 2016 These results indicate that miR-27b may promote NSCLC cell viability and enhance resistance to docetaxel treatment through direct inhibition of EGFR expression. Docetaxel 95-104 epidermal growth factor receptor Homo sapiens 144-148 27045718-1 2016 OBJECTIVE: To retrospectively analyze the relevance between DNA topoisomerase II alpha (TOP2A), epidermal growth factor receptor (EGFR) gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer (TNBC) patients. Docetaxel 168-177 epidermal growth factor receptor Homo sapiens 96-128 27045718-1 2016 OBJECTIVE: To retrospectively analyze the relevance between DNA topoisomerase II alpha (TOP2A), epidermal growth factor receptor (EGFR) gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer (TNBC) patients. Docetaxel 168-177 epidermal growth factor receptor Homo sapiens 130-134 27045718-10 2016 CONCLUSIONS: Efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in TNBC patients can be predicted by detecting TOP2A, EGFR gene expression. Docetaxel 25-34 epidermal growth factor receptor Homo sapiens 133-137 26781399-4 2016 Two of these trials, TAILOR and DELTA, which were designed to investigate treatment benefits according to EGFR genotype, demonstrated that docetaxel chemotherapy displayed significantly better in progression-free survival (PFS) when compared with the EGFR-TKI erlotinib. Docetaxel 139-148 epidermal growth factor receptor Homo sapiens 106-110 26209642-10 2015 Docetaxel remains superior independently from KRAS status for second-line treatment in EGFR wild-type advanced NSCLC patients. Docetaxel 0-9 epidermal growth factor receptor Homo sapiens 87-91 26259641-1 2015 PURPOSE: Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. Docetaxel 9-18 epidermal growth factor receptor Homo sapiens 150-154 26259641-1 2015 PURPOSE: Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. Docetaxel 9-18 epidermal growth factor receptor Homo sapiens 231-235 26259641-4 2015 METHODS: Docetaxel or pemetrexed was administered to 67 EGFR wild-type patients as a second-line treatment following one platinum-based combination chemotherapy and to 17 EGFR mutant patients as a third-line treatment following EGFR tyrosine kinase inhibitors and one platinum-based combination chemotherapy. Docetaxel 9-18 epidermal growth factor receptor Homo sapiens 56-60 26259641-9 2015 CONCLUSIONS: When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies. Docetaxel 85-94 epidermal growth factor receptor Homo sapiens 143-147 26089726-0 2015 An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre. Docetaxel 69-78 epidermal growth factor receptor Homo sapiens 107-111 26081868-2 2015 Here, we developed docetaxel-loaded vitamin E D-alpha-tocopheryl polyethylene glycol succinate (TPGS) micelles, of which the surface modified with cetuximab ligands for targeting epidermal growth factor receptors (EGFR) that are overexpressed in MDA-MB-231 breast cancer cells. Docetaxel 19-28 epidermal growth factor receptor Homo sapiens 179-212 26081868-2 2015 Here, we developed docetaxel-loaded vitamin E D-alpha-tocopheryl polyethylene glycol succinate (TPGS) micelles, of which the surface modified with cetuximab ligands for targeting epidermal growth factor receptors (EGFR) that are overexpressed in MDA-MB-231 breast cancer cells. Docetaxel 19-28 epidermal growth factor receptor Homo sapiens 214-218 26141215-0 2015 Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Docetaxel 73-82 epidermal growth factor receptor Homo sapiens 86-90 26141215-2 2015 The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. Docetaxel 97-106 epidermal growth factor receptor Homo sapiens 110-142 26141215-2 2015 The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. Docetaxel 97-106 epidermal growth factor receptor Homo sapiens 144-148 26018524-12 2015 The EGFR/ERBB2 inhibitor neratinib acted synergistically with the spindle poison docetaxel and with the Aurora kinase inhibitor GSK-1070916 in cell lines with MYC amplification. Docetaxel 81-90 epidermal growth factor receptor Homo sapiens 4-8 24888374-0 2015 EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Docetaxel 14-23 epidermal growth factor receptor Homo sapiens 0-4 25576381-5 2015 Significantly, C6 ceramide plus docetaxel caused dramatic human epidermal growth factor receptor (HER)-1/-2 degradation and downstream Akt/Erk inhibition in HER-2 expressing MDA-231 cells. Docetaxel 32-41 epidermal growth factor receptor Homo sapiens 64-104 24888374-4 2015 In this study, we explored the mechanism of EGFR-mediated docetaxel resistance in PC. Docetaxel 58-67 epidermal growth factor receptor Homo sapiens 44-48 24888374-7 2015 Cellular resistance to docetaxel was significantly associated with increased EGFR and EGFR activation in PC/DX25. Docetaxel 23-32 epidermal growth factor receptor Homo sapiens 77-81 24888374-7 2015 Cellular resistance to docetaxel was significantly associated with increased EGFR and EGFR activation in PC/DX25. Docetaxel 23-32 epidermal growth factor receptor Homo sapiens 86-90 24888374-8 2015 There was a dose-dependent increase in EGFR expression associated with the magnitude of docetaxel resistance. Docetaxel 88-97 epidermal growth factor receptor Homo sapiens 39-43 24888374-11 2015 We showed that docetaxel sensitivity can be stored in PC/DX25 cells by knockdown and inactivation of EGFR expression through EGFR siRNA and specific inhibitors, respectively. Docetaxel 15-24 epidermal growth factor receptor Homo sapiens 101-105 24888374-11 2015 We showed that docetaxel sensitivity can be stored in PC/DX25 cells by knockdown and inactivation of EGFR expression through EGFR siRNA and specific inhibitors, respectively. Docetaxel 15-24 epidermal growth factor receptor Homo sapiens 125-129 24888374-12 2015 Contrarily, overexpression of EGFR or recombinant EGF protein treatment could rescue PC3 cells from docetaxel-mediated cytotoxicity. Docetaxel 100-109 epidermal growth factor receptor Homo sapiens 30-34 24888374-14 2015 Moreover, EGFR-mediated docetaxel resistance occurred through the Akt-dependent ABCB1 expression in PC cells. Docetaxel 24-33 epidermal growth factor receptor Homo sapiens 10-14 24888374-15 2015 These findings demonstrated EGFR played an important role in docetaxel-resistant PC and EGFR inhibition may enhance the therapeutic efficacy of docetaxel-based treatment. Docetaxel 61-70 epidermal growth factor receptor Homo sapiens 28-32 24888374-15 2015 These findings demonstrated EGFR played an important role in docetaxel-resistant PC and EGFR inhibition may enhance the therapeutic efficacy of docetaxel-based treatment. Docetaxel 144-153 epidermal growth factor receptor Homo sapiens 28-32 24888374-15 2015 These findings demonstrated EGFR played an important role in docetaxel-resistant PC and EGFR inhibition may enhance the therapeutic efficacy of docetaxel-based treatment. Docetaxel 144-153 epidermal growth factor receptor Homo sapiens 88-92 25057173-10 2014 CONCLUSIONS: High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line NSCLC. Docetaxel 175-184 epidermal growth factor receptor Homo sapiens 18-22 25854383-8 2015 However, combination therapy with EGFR-TKI and chemotherapy after failure of first-line chemotherapy significantly improved the ORR (RR 2.06 [1.42, 2.99], p=0.0002), PFS (HR 0.71 [0.61, 0.82], p<0.00001) and OS (HR 0.74 [0.62- 0.88], p=0.0008), clinical benefit being restricted to combining EGFR-TKI with pemetrexed, but not docetaxel. Docetaxel 329-338 epidermal growth factor receptor Homo sapiens 34-38 25474307-10 2014 Mechanism studies showed that docetaxel-induced phosphorylation of EGFR and ERK was repressed by subsequently used gefitinib, but not by concurrent exposure of gefitinib. Docetaxel 30-39 epidermal growth factor receptor Homo sapiens 67-71 25474307-11 2014 The gefitinib-repressed phosphorylation of EGFR and ERK was reversed neither by concurrent nor by subsequent administration of docetaxel. Docetaxel 127-136 epidermal growth factor receptor Homo sapiens 43-47 25219817-5 2014 In pretreated NSCLC, EGFR-TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy with docetaxel or pemetrexed in terms of survival has been demonstrated. Docetaxel 210-219 epidermal growth factor receptor Homo sapiens 21-25 25059320-10 2014 Patients with EGFR mutations had better response to docetaxel compared with wild-type patients (26 vs. 17%, p = 0.028). Docetaxel 52-61 epidermal growth factor receptor Homo sapiens 14-18 25016642-0 2014 Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells. Docetaxel 65-74 epidermal growth factor receptor Homo sapiens 93-125 25016642-3 2014 The present work investigated the preparation and characterization of docetaxel (DTXL) loaded gamma-poly (glutamic acid) (gamma-PGA) nanoparticles (Nps) conjugated with EGFR antibody (Cetuximab, CET) targeted to colon cancer cells (HT-29), highly over expressing EGFR. Docetaxel 70-79 epidermal growth factor receptor Homo sapiens 169-173 25016642-3 2014 The present work investigated the preparation and characterization of docetaxel (DTXL) loaded gamma-poly (glutamic acid) (gamma-PGA) nanoparticles (Nps) conjugated with EGFR antibody (Cetuximab, CET) targeted to colon cancer cells (HT-29), highly over expressing EGFR. Docetaxel 70-79 epidermal growth factor receptor Homo sapiens 263-267 25016642-3 2014 The present work investigated the preparation and characterization of docetaxel (DTXL) loaded gamma-poly (glutamic acid) (gamma-PGA) nanoparticles (Nps) conjugated with EGFR antibody (Cetuximab, CET) targeted to colon cancer cells (HT-29), highly over expressing EGFR. Docetaxel 81-85 epidermal growth factor receptor Homo sapiens 169-173 25016642-3 2014 The present work investigated the preparation and characterization of docetaxel (DTXL) loaded gamma-poly (glutamic acid) (gamma-PGA) nanoparticles (Nps) conjugated with EGFR antibody (Cetuximab, CET) targeted to colon cancer cells (HT-29), highly over expressing EGFR. Docetaxel 81-85 epidermal growth factor receptor Homo sapiens 263-267 24682085-0 2014 Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. Docetaxel 63-72 epidermal growth factor receptor Homo sapiens 76-80 24841974-6 2014 EGFR wild-type NSCLC was present in 109 and 90 patients in the erlotinib and docetaxel groups, respectively. Docetaxel 77-86 epidermal growth factor receptor Homo sapiens 0-4 24682085-2 2014 The purpose of the current study was to investigate the antitumor effects of gefitinib in combination with docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human lung cancer cell lines and the associated molecular mechanisms. Docetaxel 107-116 epidermal growth factor receptor Homo sapiens 120-124 24682085-7 2014 Coadministration of gefitinib and docetaxel was observed to result in superior inhibition of tumor cell proliferation, however, increased rates of apoptosis were only observed in EGFR-TKI-sensitive cells, whereas, antagonistic activity was observed in the EGFR-TKI-resistant cell lines. Docetaxel 34-43 epidermal growth factor receptor Homo sapiens 179-183 24682085-7 2014 Coadministration of gefitinib and docetaxel was observed to result in superior inhibition of tumor cell proliferation, however, increased rates of apoptosis were only observed in EGFR-TKI-sensitive cells, whereas, antagonistic activity was observed in the EGFR-TKI-resistant cell lines. Docetaxel 34-43 epidermal growth factor receptor Homo sapiens 256-260 24682085-9 2014 In addition, in cells exhibiting a synergistic interaction between gefitinib and docetaxel, an increase in p-EGFR and p-AKT was observed following chemotherapy exposure. Docetaxel 81-90 epidermal growth factor receptor Homo sapiens 109-113 24682085-10 2014 By contrast, in cells exhibiting no change or a decrease in p-EGFR and p-AKT following docetaxel treatment, an antagonistic interaction between the two agents was observed. Docetaxel 87-96 epidermal growth factor receptor Homo sapiens 62-66 24682085-11 2014 In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. Docetaxel 34-43 epidermal growth factor receptor Homo sapiens 91-95 24682085-12 2014 The results also indicate that the interactions between gefitinib and docetaxel may be associated with the effect of docetaxel on EGFR phosphorylation. Docetaxel 70-79 epidermal growth factor receptor Homo sapiens 130-134 24682085-12 2014 The results also indicate that the interactions between gefitinib and docetaxel may be associated with the effect of docetaxel on EGFR phosphorylation. Docetaxel 117-126 epidermal growth factor receptor Homo sapiens 130-134 24155892-0 2013 Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer. Docetaxel 117-126 epidermal growth factor receptor Homo sapiens 23-55 23910066-8 2013 Among the patients with EGFR mutations, the disease control rate for docetaxel was higher than for gemcitabine-based therapy (P = .031). Docetaxel 69-78 epidermal growth factor receptor Homo sapiens 24-28 23910066-9 2013 In addition, docetaxel or vinorelbine showed a longer PFS than gemcitabine-based chemotherapy in patients with EGFR mutations (P = .033 and P = .028). Docetaxel 13-22 epidermal growth factor receptor Homo sapiens 111-115 23910066-12 2013 In patients with EGFR mutations, PFS for docetaxel and gemcitabine was higher than for vinorelbine-based chemotherapies. Docetaxel 41-50 epidermal growth factor receptor Homo sapiens 17-21 24155892-11 2013 Based on previous preclinical research, we conclude that simultaneously blocking EGFR and COX-2 by gefitinib and NS-398 sensitizes advanced PCa cells to docetaxel-induced cytotoxicity. Docetaxel 153-162 epidermal growth factor receptor Homo sapiens 81-85 23192362-8 2013 Activation of EGFR expressed on MSCs by PC3-CM enhanced their capability to increase PC3 cells proliferation and to inhibit Docetaxel activity. Docetaxel 124-133 epidermal growth factor receptor Homo sapiens 14-18 23590835-13 2013 We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib. Docetaxel 148-157 epidermal growth factor receptor Homo sapiens 36-40 23493804-0 2013 Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. Docetaxel 0-9 epidermal growth factor receptor Homo sapiens 65-69 23493804-7 2013 To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors. Docetaxel 69-78 epidermal growth factor receptor Homo sapiens 134-138 23493804-7 2013 To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors. Docetaxel 69-78 epidermal growth factor receptor Homo sapiens 192-196 22977195-2 2012 The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer. Docetaxel 19-28 epidermal growth factor receptor Homo sapiens 76-80 21947696-0 2012 Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Docetaxel 164-173 epidermal growth factor receptor Homo sapiens 79-111 22994780-7 2012 Treatment with TSA/TXT or TSA/erlotinib led to a significant increase of cleaved caspase-3 expression, also resulting in elevated acetylation of alpha-tubulin or hsp90 and decreased expression of EGFR, which was negatively associated with the level of acetylated hsp90. Docetaxel 19-22 epidermal growth factor receptor Homo sapiens 196-200 22429575-13 2012 CONCLUSIONS: The docetaxel administration following gefitinib might be a new stratagy for lung cancer with T790M mutation after having EGFR-TKIs resistance. Docetaxel 17-26 epidermal growth factor receptor Homo sapiens 135-139 21569641-9 2011 Docetaxel increased, and gefitinib decreased, the phosphorylation of EGFR and ERK respectively. Docetaxel 0-9 epidermal growth factor receptor Homo sapiens 69-73 22848267-10 2011 In conclusion, this retrospective study suggests that non-squamous histology and favorable therapeutic effect from EGFR-TKIs are useful markers for predicting the efficacy of docetaxel in second-line therapy for NSCLC. Docetaxel 175-184 epidermal growth factor receptor Homo sapiens 115-119 21681119-0 2011 Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. Docetaxel 63-72 epidermal growth factor receptor Homo sapiens 0-32 21796416-0 2011 Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. Docetaxel 46-55 epidermal growth factor receptor Homo sapiens 114-118 20705357-6 2011 Patients who had received first-line docetaxel/cisplatin attained an overall survival of 19.2 months when treated with second-line EGFR TKIs, in comparison with 10.7 months when treated with second-line chemotherapy (P = 0.0002). Docetaxel 37-46 epidermal growth factor receptor Homo sapiens 131-135 20864569-5 2011 Promising results were shown in phase II trials in which the anti-epidermal growth factor receptor monoclonal antibody cetuximab was added to induction therapy with TPF, docetaxel/cisplatin, or paclitaxel/carboplatin, and in some of these studies, to subsequent CRT. Docetaxel 170-179 epidermal growth factor receptor Homo sapiens 66-98 20705357-7 2011 However, for patients who had received first-line docetaxel/gemcitabine, overall survival was 14.8 months with EGFR TKIs and 10.8 months with chemotherapy (P = 0.29). Docetaxel 50-59 epidermal growth factor receptor Homo sapiens 111-115 21197560-7 2011 Moreover, over-expression of miR-143 in prostate cancer cells suppressed their proliferation and migration and increased their sensitivity to docetaxel by targeting EGFR/RAS/MAPK pathway. Docetaxel 142-151 epidermal growth factor receptor Homo sapiens 165-169 20878103-0 2010 Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Docetaxel 76-85 epidermal growth factor receptor Homo sapiens 133-137 20665703-1 2011 Chemotherapy employing paclitaxel and docetaxel is widely used for treating early-stage breast cancer and metastasis, which is frequently associated with overexpression of epidermal growth factor receptor (EGFR) and resistance to apoptosis. Docetaxel 38-47 epidermal growth factor receptor Homo sapiens 172-204 20665703-1 2011 Chemotherapy employing paclitaxel and docetaxel is widely used for treating early-stage breast cancer and metastasis, which is frequently associated with overexpression of epidermal growth factor receptor (EGFR) and resistance to apoptosis. Docetaxel 38-47 epidermal growth factor receptor Homo sapiens 206-210 21035484-6 2011 Interesting the prostate CICs could be rendered more sensitive to docetaxel by inclusion of suboptimal doses of genistein, cyclopamine, and EGFR inhibitors. Docetaxel 66-75 epidermal growth factor receptor Homo sapiens 140-144 20878103-0 2010 Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Docetaxel 76-85 epidermal growth factor receptor Homo sapiens 180-184 20878103-4 2010 The purpose of the present study was to determine the optimum novel regimen of erlotinib and docetaxel against NSCLC cells which have EGFR mutation (HCC827 cells), KRAS mutation (A549 cells) or both wild-type (NCI-H292 cells). Docetaxel 93-102 epidermal growth factor receptor Homo sapiens 134-138 20022809-13 2010 INTERPRETATION: Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel. Docetaxel 195-204 epidermal growth factor receptor Homo sapiens 62-66 20513026-9 2010 The expression of E2F and EGFR were decreased in both XRP6258 and docetaxel-treated HNSCC cells. Docetaxel 66-75 epidermal growth factor receptor Homo sapiens 26-30 20179163-1 2010 The present study has been undertaken to establish the therapeutic benefit of cotargeting epidermal growth factor receptor (EGFR) and sonic hedgehog pathways by using gefitinib and cyclopamine, respectively, for improving the efficacy of the current chemotherapeutic drug docetaxel to counteract the prostate cancer progression from locally invasive to metastatic and recurrent disease stages. Docetaxel 272-281 epidermal growth factor receptor Homo sapiens 90-122 20179163-1 2010 The present study has been undertaken to establish the therapeutic benefit of cotargeting epidermal growth factor receptor (EGFR) and sonic hedgehog pathways by using gefitinib and cyclopamine, respectively, for improving the efficacy of the current chemotherapeutic drug docetaxel to counteract the prostate cancer progression from locally invasive to metastatic and recurrent disease stages. Docetaxel 272-281 epidermal growth factor receptor Homo sapiens 124-128 20179163-7 2010 Altogether, these observations suggest that EGFR and sonic hedgehog cascades may represent the potential therapeutic targets of great clinical interest to eradicate the total prostate cancer cell mass and improve the current docetaxel-based therapies against locally advanced and invasive prostate cancers, and thereby prevent metastases and disease relapse. Docetaxel 225-234 epidermal growth factor receptor Homo sapiens 44-48 20038723-5 2010 EGFR mutation-positive patients had longer progression-free survival (PFS; hazard ratio [HR], 0.16; 95% CI, 0.05 to 0.49; P = .001) and higher objective response rate (ORR; 42.1% v 21.1%; P = .04), and patients with high EGFR copy number had higher ORR (13.0% v 7.4%; P = .04) with gefitinib versus docetaxel. Docetaxel 299-308 epidermal growth factor receptor Homo sapiens 0-4 20038723-7 2010 For secondary end points of PFS and ORR, some advantages for gefitinib over docetaxel were seen in EGFR mutation-positive and high EGFR copy number patients. Docetaxel 76-85 epidermal growth factor receptor Homo sapiens 99-103 20038723-7 2010 For secondary end points of PFS and ORR, some advantages for gefitinib over docetaxel were seen in EGFR mutation-positive and high EGFR copy number patients. Docetaxel 76-85 epidermal growth factor receptor Homo sapiens 131-135 19530244-8 2009 On comparing the efficacy of gefitinib with that of docetaxel, it was found that the median progression-free survival was significantly longer for patients treated with gefitinib than those with docetaxel in those harboring plasma EGFR mutation (7.609 vs. 3.192 months, p = 0.006). Docetaxel 52-61 epidermal growth factor receptor Homo sapiens 231-235 20028750-0 2010 Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Docetaxel 171-180 epidermal growth factor receptor Homo sapiens 15-47 20028750-9 2010 CONCLUSIONS: Our study revealed an influence of the EGFR-R521K genotype on skin toxicity and suggested its relation to clinical activity of cetuximab/docetaxel treatment. Docetaxel 150-159 epidermal growth factor receptor Homo sapiens 52-56 23074402-37 2010 The INTEREST trial further indicated that patients with EGFR mutations had prolonged PFS and higher ORR when treated with gefitinib compared with docetaxel. Docetaxel 146-155 epidermal growth factor receptor Homo sapiens 56-60 19884861-0 2009 EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. Docetaxel 89-98 epidermal growth factor receptor Homo sapiens 0-4 19884861-10 2009 CONCLUSIONS: Activating EGFR mutations detected in shed DNA in plasma are significantly associated with favorable outcomes in patients with advanced NSCLC receiving docetaxel plus intercalated erlotinib. Docetaxel 165-174 epidermal growth factor receptor Homo sapiens 24-28 19530244-8 2009 On comparing the efficacy of gefitinib with that of docetaxel, it was found that the median progression-free survival was significantly longer for patients treated with gefitinib than those with docetaxel in those harboring plasma EGFR mutation (7.609 vs. 3.192 months, p = 0.006). Docetaxel 195-204 epidermal growth factor receptor Homo sapiens 231-235 19352302-6 2009 Tumors that were intrinsically sensitive or resistant to doxorubicin or docetaxel evoked distinct gene expression changes in response to the drug; doxorubicin-resistant tumors upregulated genes that were enriched for ErbB signaling, ubiquitin-mediated proteolysis, TGF-beta signaling, and MAP-kinase signaling pathways, whereas docetaxel-resistant tumors upregulated genes that were enriched for focal adhesion and regulation of actin cytoskeleton. Docetaxel 72-81 epidermal growth factor receptor Homo sapiens 217-221 19399750-0 2009 Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. Docetaxel 88-97 epidermal growth factor receptor Homo sapiens 49-53 19399750-1 2009 BACKGROUND: This study was to explore whether the efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Z, Iressa, gefitinib) plus chemotherapeutic agents docetaxel (D) and cisplatin (P) may benefit from sequencing of the combination. Docetaxel 191-200 epidermal growth factor receptor Homo sapiens 66-98 19399750-1 2009 BACKGROUND: This study was to explore whether the efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Z, Iressa, gefitinib) plus chemotherapeutic agents docetaxel (D) and cisplatin (P) may benefit from sequencing of the combination. Docetaxel 191-200 epidermal growth factor receptor Homo sapiens 100-104 19352302-6 2009 Tumors that were intrinsically sensitive or resistant to doxorubicin or docetaxel evoked distinct gene expression changes in response to the drug; doxorubicin-resistant tumors upregulated genes that were enriched for ErbB signaling, ubiquitin-mediated proteolysis, TGF-beta signaling, and MAP-kinase signaling pathways, whereas docetaxel-resistant tumors upregulated genes that were enriched for focal adhesion and regulation of actin cytoskeleton. Docetaxel 328-337 epidermal growth factor receptor Homo sapiens 217-221 18758819-0 2009 In vitro effect of radiation, antibody to epidermal growth factor receptor and Docetaxel in human head and neck squamous carcinoma cells with mutant P53 and over-expressed EGFR. Docetaxel 79-88 epidermal growth factor receptor Homo sapiens 172-176 19229369-7 2009 Quality of life and symptom improvement for patients treated with an EGFR-TKI appear better than they do for patients treated with second-line docetaxel. Docetaxel 143-152 epidermal growth factor receptor Homo sapiens 69-73 18799900-7 2008 Docetaxel has been established as standard therapy for recurrent cases, but based on the results of recent comparative studies, a survival-prolonging effect has been shown for pemetrexed and for EGFR tyrosine kinase inhibitors (gefitinib, erlotinib), which are molecularly targeted drugs, and it has now become possible to select treatment methods by choosing from a number of anticancer drugs. Docetaxel 0-9 epidermal growth factor receptor Homo sapiens 195-199 18418213-9 2008 The low and high doses of docetaxel had opposite effects on EGFR expression: a decrease and an increase, respectively. Docetaxel 26-35 epidermal growth factor receptor Homo sapiens 60-64 18418213-10 2008 The dose of docetaxel affects sequence-dependent cytotoxicity when docetaxel is combined with an EGFR inhibitor. Docetaxel 12-21 epidermal growth factor receptor Homo sapiens 97-101 18418213-11 2008 The mechanism for this difference is a combination of the dose-dependent effects of docetaxel on the mode of cell death and on EGFR expression. Docetaxel 84-93 epidermal growth factor receptor Homo sapiens 127-131 18025070-8 2008 Administration of EGFR antisense oligonucleotides in combination with docetaxel improved antitumor efficacy and resulted in lower expression levels of EGFR, fewer proliferating cells, and more apoptotic cells in the tumors compared with controls. Docetaxel 70-79 epidermal growth factor receptor Homo sapiens 151-155 18025070-9 2008 Systemic administration of phosphorothioated EGFR antisense oligonucleotides for 30 days increased the retention of docetaxel in the tumor by approximately 4-fold compared with tumors treated with docetaxel alone or docetaxel and EGFR sense oligonucleotides (P < 0.05). Docetaxel 116-125 epidermal growth factor receptor Homo sapiens 45-49 18025070-9 2008 Systemic administration of phosphorothioated EGFR antisense oligonucleotides for 30 days increased the retention of docetaxel in the tumor by approximately 4-fold compared with tumors treated with docetaxel alone or docetaxel and EGFR sense oligonucleotides (P < 0.05). Docetaxel 197-206 epidermal growth factor receptor Homo sapiens 45-49 18025070-9 2008 Systemic administration of phosphorothioated EGFR antisense oligonucleotides for 30 days increased the retention of docetaxel in the tumor by approximately 4-fold compared with tumors treated with docetaxel alone or docetaxel and EGFR sense oligonucleotides (P < 0.05). Docetaxel 197-206 epidermal growth factor receptor Homo sapiens 45-49 18025070-10 2008 Combination of EGFR antisense oligonucleotides with low doses of docetaxel has antitumor efficacy, and it may be an effective treatment strategy for SCCHN. Docetaxel 65-74 epidermal growth factor receptor Homo sapiens 15-19 17638896-8 2007 IL8-S cells expressed 2- to 3-fold higher levels of phospho-EGFR, src, Akt, and nuclear factor kappaB (NF-kappaB) and showed increased survival when treated with docetaxel. Docetaxel 162-171 epidermal growth factor receptor Homo sapiens 60-64 17505004-10 2007 CONCLUSIONS: Our studies suggest that the combination of docetaxel with a cyclooxygenase-2 inhibitor and an epidermal growth factor receptor tyrosine kinase inhibitor may further improve efficacy of docetaxel and other taxane-based therapies in squamous cell carcinoma of the head and neck. Docetaxel 199-208 epidermal growth factor receptor Homo sapiens 108-140 17363490-0 2007 Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Docetaxel 155-164 epidermal growth factor receptor Homo sapiens 22-54 17505004-0 2007 Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Docetaxel 15-24 epidermal growth factor receptor Homo sapiens 58-90 15897421-11 2005 Supradose levels of docetaxel produced distinct protein expression patterns for regulators of the cell cycle (cyclins A and B, p21, and p27), apoptosis (cleaved caspase-3 and cleaved PARP), and signal transduction (EGFR, pEGFR, pc-Jun, and pERK) in HNSCC, which supports a distinctive mechanism of action for supradose docetaxel levels. Docetaxel 20-29 epidermal growth factor receptor Homo sapiens 215-219 16984384-0 2006 Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Docetaxel 124-133 epidermal growth factor receptor Homo sapiens 32-64 16984384-7 2006 Treatment with EGFR siRNA in combination with cisplatin, 5-FU and docetaxel enhanced chemosensitivity with a significant increase in apoptosis. Docetaxel 66-75 epidermal growth factor receptor Homo sapiens 15-19 16984384-9 2006 These cumulative results suggest that EGFR siRNA combined with cisplatin, 5-FU and docetaxel may be a feasible strategy to enhance the effects of chemotherapy in patients with HNSCC. Docetaxel 83-92 epidermal growth factor receptor Homo sapiens 38-42 15985306-1 2005 BACKGROUND: Gefitinib is the first approved EGFR tyrosine-kinase inhibitor indicated for the treatment of patients with locally advanced (IIIB) or metastatic NSCLC after failure of platinum-based first-line therapy and docetaxel chemotherapy. Docetaxel 219-228 epidermal growth factor receptor Homo sapiens 44-48 15234052-15 2004 CONCLUSIONS: Our results show that C225 anti-EGFR antibody is a potent enhancer of tumor response to docetaxel or radiation as single agents, and to docetaxel when combined with radiation. Docetaxel 101-110 epidermal growth factor receptor Homo sapiens 45-49 15332713-0 2004 Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. Docetaxel 26-35 epidermal growth factor receptor Homo sapiens 39-43 15332713-4 2004 The aim of the present work was to compare the cytotoxic effect of taxanes, paclitaxel and docetaxel on the EGFR-expressing carcinoma cell lines A431, MDA-MB-231 and NCI-H358 under normoxic and hypoxic conditions. Docetaxel 91-100 epidermal growth factor receptor Homo sapiens 108-112 15234052-15 2004 CONCLUSIONS: Our results show that C225 anti-EGFR antibody is a potent enhancer of tumor response to docetaxel or radiation as single agents, and to docetaxel when combined with radiation. Docetaxel 149-158 epidermal growth factor receptor Homo sapiens 45-49 12473607-15 2002 Epidermal growth factor receptor, activated epidermal growth factor receptor, and activated c-Jun NH(2)-terminal kinase expression was lowered by docetaxel. Docetaxel 146-155 epidermal growth factor receptor Homo sapiens 0-32 14657531-4 2003 Randomized clinical trials of the EGFR-TK inhibitor gefitinib have demonstrated clinical benefits in patients with advanced non-small cell lung cancer whose disease had previously progressed on platinum- and docetaxel-based chemotherapy regimens. Docetaxel 208-217 epidermal growth factor receptor Homo sapiens 34-38 12473607-15 2002 Epidermal growth factor receptor, activated epidermal growth factor receptor, and activated c-Jun NH(2)-terminal kinase expression was lowered by docetaxel. Docetaxel 146-155 epidermal growth factor receptor Homo sapiens 44-76 7833145-0 1994 Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Docetaxel 45-54 epidermal growth factor receptor Homo sapiens 98-130 7833145-0 1994 Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Docetaxel 56-64 epidermal growth factor receptor Homo sapiens 98-130